Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 2016

View Archived Issues

Asceneuron discloses glycosidase inhibitors

PharmaResearch Products and Lipopeptide establish strategic collaboration in wound care

Scientists report miRNAs that may be associated with mBCC

PsiOxus Therapeutics begins combination treatment in OCTAVE study

Gilead Sciences patents compounds to treat HIV

Han Wha Pharma and Yang Ji Chemical disclose JAK inhibitors

Prexton Therapeutics introduces mGlu4 receptor PAMs

Bristol-Myers Squibb describes HIV integrase inhibitors

University of Dayton reports antineoplastic and antibacterial compounds

AnaptysBio starts dosing in first-in-human phase I trial of ANB-020

Senhwa Biosciences enters agreement with CCTG for phase I/II study of CX-5461

Vericel releases topline results from phase IIb study of ixmyelocel-T

Phase III data show sarilumab superior to adalimumab in patients with active rheumatoid arthritis

FDA accepts for review Enbrel sBLA for pediatric chronic severe plaque psoriasis

Scancell and Karolinska Institutet collaborate to explore role of citrullination in cancer

Double-blind trial evaluates mexiletine in sporadic amyotrophic lateral sclerosis

SRI International awarded National Cancer Institute contract to develop cancer treatments

Bioresorbable sensors may enable wireless data collection in deep tissue and body cavities

Lundbeck initiates phase III program of Lu-AF-35700 for treatment-resistant schizophrenia

Enrollment under way in phase III trial of elafibranor for NASH

Novartis submits sBLA for ofatumumab with fludarabine and cyclophosphamide for relapsed CLL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...